Evidence map›Paper›PMID 25214764›Full record

ArticleDrug design, development and therapy2014

Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity.

Can Chen, Ting Wang, Fengbo Wu, Wei Huang, Gu He, Liang Ouyang, Mingli Xiang, Cheng Peng, Qinglin Jiang

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. A critical review of the role of MBiochimica et biophysica acta. Reviews on cancer · 2019
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Can ChenState Key Laboratory of Biotherapy and Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People's Republic of China ; College of Pharmacy and the First Affiliated Hospital, Chengdu Medical College, Chengdu, People's Republic of China.
Ting WangState Key Laboratory of Biotherapy and Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People's Republic of China ; Department of Cardiology, General Hospital of Chengdu Military Command, Chengdu, People's Republic of China.
Fengbo WuState Key Laboratory of Biotherapy and Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Wei HuangState Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Gu HeState Key Laboratory of Biotherapy and Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Liang OuyangState Key Laboratory of Biotherapy and Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Mingli XiangState Key Laboratory of Biotherapy and Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Cheng PengState Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Qinglin JiangState Key Laboratory of Biotherapy and Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People's Republic of China ; College of Pharmacy and the First Affiliated Hospital, Chengdu Medical College, Chengdu, People's Republic of China.
State Key Laboratory of BiotherapyChengdu University of Traditional Chinese Medicine · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compared with normal differentiated cells, cancer cells upregulate the expression of pyruvate kinase isozyme M2 (PKM2) to support glycolytic intermediates for anabolic processes, including the synthesis of nucleic acids, amino acids, and lipids. In this study, a combination of the structure-based pharmacophore modeling and a hybrid protocol of virtual screening methods comprised of pharmacophore model-based virtual screening, docking-based virtual screening, and in silico ADMET (absorption, distribution, metabolism, excretion and toxicity) analysis were used to retrieve novel PKM2 activators from commercially available chemical databases. Tetrahydroquinoline derivatives were identified as potential scaffolds of PKM2 activators. Thus, the hybrid virtual screening approach was applied to screen the focused tetrahydroquinoline derivatives embedded in the ZINC database. Six hit compounds were selected from the final hits and experimental studies were then performed. Compound 8 displayed a potent inhibitory effect on human lung cancer cells. Following treatment with Compound 8, cell viability, apoptosis, and reactive oxygen species (ROS) production were examined in A549 cells. Finally, we evaluated the effects of Compound 8 on mice xenograft tumor models in vivo. These results may provide important information for further research on novel PKM2 activators as antitumor agents.

Indexed as

Drug DiscoveryAnimalsAntineoplastic AgentsApoptosisCarrier ProteinsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorFlow CytometryHumansMembrane ProteinsMiceModels, MolecularMolecular Structure1,2,3,4-tetrahydroquinolineAntineoplastic AgentsCarrier ProteinsMembrane ProteinsQuinolinesReactive Oxygen SpeciesThyroid Hormone-Binding ProteinsThyroid Hormonesmolecular dockingpharmacophorepyruvate kinasevirtual screening

Identifiers

PMID25214764
PMCPMC4159224
OpenAlexW2056931571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.